SCHEMBL1011288

SCHEMBL1011288

Cc1[nH]c2c(N)cccc2c1C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.64
MAPT P10636 4/20 0.51
NPC1 O15118 1/20 0.51
MAPK1 P28482 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PARP1 P09874 4/20 0.48
CYP3A4 P08684 4/20 0.46
TSHR P16473 3/20 0.46
PIK3CA P42336 1/20 0.46
POLB P06746 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
BLM P54132 1/20 0.45
MCL1 Q07820 1/20 0.45
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29926224 1.00 AHR (0.64) AHRMAPTNPC1MAPK1L3MBTL1
SCHEMBL5341593 0.78 AHR (1.00) AHRMAPTNPC1MAPK1L3MBTL1
SCHEMBL8650444 0.77 MAPT (0.44) AHRMAPTPARP1CYP3A4TSHR
SCHEMBL30983620 0.77 PARP1 (0.65) MAPTPARP1CYP3A4TSHRPIK3CA
SCHEMBL3073008 0.77 PARP1 (0.65) MAPTPARP1CYP3A4TSHRPIK3CA
SCHEMBL8030947 0.77 ALDH1A1 (0.55) AHRMAPTNPC1MAPK1L3MBTL1
SCHEMBL6185787 0.76 MCL1 (0.62) MAPTNPC1L3MBTL1PARP1CYP3A4
Hydrochloric Acid SCHEMBL9445592 0.75 ALDH1A1 (0.53) AHRMAPTNPC1MAPK1L3MBTL1
SCHEMBL21646227 0.75 AHR (0.64) AHRMAPTNPC1MAPK1L3MBTL1
SCHEMBL5503927 0.75 AHR (0.64) AHRMAPTNPC1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 US claimed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 US claimed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 US claimed
EP-1819341-A2 IL-12 MODULATORY COMPOUNDS Synta Pharmaceuticals Corporation (US) 2007-08-22 EP claimed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 US claimed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 WO claimed
US-5752982-A DYEING HAIR IN LIGHTFAST, WASHFAST COLORS L'OREAL (FR) 1998-05-19 US claimed
EP-0578735-B1 NOVEL KERATIN FIBRE DYEING METHOD USING AMINOINDOLES, WITH ACID pH, COMPOSITIONS THEREFOR AND NOVEL AMINOINDOLE COMPOUNDS OREAL (FR) 1996-01-03 EP claimed
EP-0460996-B1 Keratinic fibres dyeing process with an aminoindol associated with a quinone derivative OREAL (FR) 1994-09-14 EP claimed
EP-0425345-B1 Keratinic fibres dyeing process with amino-indoles, composition and use devices OREAL (FR) 1994-09-14 EP claimed
EP-0578735-A1 NOVEL KERATIN FIBRE DYEING METHOD USING AMINOINDOLES, WITH ACID pH, COMPOSITIONS THEREFOR AND NOVEL AMINOINDOLE COMPOUNDS. OREAL (FR) 1994-01-19 EP claimed
US-5254135-A Applying indole dye, developing with oxidizing system L'OREAL (FR) 1993-10-19 US claimed
US-5180400-A METHOD FOR DYEING KERATINOUS FIBRES USING AN AMINOINDOLE IN COMBINATION WITH A QUINONE DERIVATIVE L'OREAL (FR) 1993-01-19 US claimed
WO-1992017157-A1 NOVEL KERATIN FIBRE DYEING METHOD USING AMINOINDOLES, WITH ACID pH, COMPOSITIONS THEREFOR AND NOVEL AMINOINDOLE COMPOUNDS L'OREAL (FR) 1992-10-15 WO claimed
EP-0460996-A1 Keratinic fibres dyeing process with an aminoindol associated with a quinone derivative L'OREAL (FR) 1991-12-11 EP claimed
CN-1051670-A Contain the dyeing composition for keratinous fibres of oxidation dye parent and amino indole colour former, the colouring method that uses these compositionss and noval chemical compound OREAL (FR) 1991-05-29 CN claimed
CN-115087658-A Sulfonamide or sulfenamide compounds having BRD 4-inducing proteolytic activity, and pharmaceutical use thereof 田边三菱制药株式会社 2022-09-20 CN disclosed
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 US disclosed
EP-0460996-A1 Keratinic fibres dyeing process with an aminoindol associated with a quinone derivative L'OREAL (FR) 1991-12-11 EP disclosed
EP-0425345-A1 Keratinic fibres dyeing process with amino-indoles, composition and use devices L'OREAL (FR) 1991-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223996-A1 IL-12 modulatory compounds IL2, IL4, IFNG AHR 463/4885MAPT 3259/4885NPC1 2094/4885
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS REL, NFATC1, BCL6 AHR 3534/4885MAPT 4316/4885NPC1 2090/4885
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG AHR 463/4885MAPT 3259/4885NPC1 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.